CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 503 filers reported holding CRISPR THERAPEUTICS AG in Q2 2021. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $27,167 | -87.4% | 503 | -84.1% | 0.00% | -75.0% |
| Q1 2024 | $215,863 | +667.0% | 3,167 | +597.6% | 0.00% | +300.0% |
| Q4 2023 | $28,143 | -41.1% | 454 | -56.8% | 0.00% | -50.0% |
| Q3 2023 | $47,750 | +7.3% | 1,052 | +32.7% | 0.00% | 0.0% |
| Q2 2023 | $44,519 | +150.5% | 793 | +101.8% | 0.00% | +100.0% |
| Q1 2023 | $17,775 | +118400.0% | 393 | +5.4% | 0.00% | 0.0% |
| Q4 2022 | $15 | -99.9% | 373 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $24,000 | +4.3% | 373 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $23,000 | -72.3% | 373 | -65.8% | 0.00% | -50.0% |
| Q4 2021 | $83,000 | +654.5% | 1,090 | +990.0% | 0.00% | – |
| Q3 2021 | $11,000 | -31.2% | 100 | 0.0% | 0.00% | – |
| Q2 2021 | $16,000 | -63.6% | 100 | -74.2% | 0.00% | -100.0% |
| Q1 2021 | $44,000 | – | 388 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $37,781,000 | 20.21% |
| Ariose Capital Management Ltd | 37,900 | $2,872,000 | 6.78% |
| EcoR1 Capital, LLC | 1,077,483 | $81,652,000 | 2.60% |
| NEA Management Company, LLC | 1,590,002 | $120,490,000 | 2.44% |
| ARK Investment Management | 9,087,868 | $688,679,000 | 2.08% |
| NIA IMPACT ADVISORS, LLC | 62,609 | $3,876,000 | 2.06% |
| Deuterium Capital Management, LLC | 18,000 | $1,364,000 | 2.02% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 108,200 | $8,192,000 | 1.82% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,789,000 | 1.76% |
| Nikko Asset Management Americas, Inc. | 4,319,471 | $330,526,000 | 1.74% |